Sign in Sign up for free

Last updated: 1 July 2024 at 6:21pm EST

Kristina Burow Net Worth




The estimated Net Worth of Kristina Burow is at least $471 Thousand dollars as of 18 September 2020. Ms. Burow owns over 230,000 units of Gossamer Bio stock worth over $141,273 and over the last 7 years she sold GOSS stock worth over $0. In addition, she makes $329,937 as Independent Director at Gossamer Bio.

Ms. Burow GOSS stock SEC Form 4 insiders trading

Kristina has made over 3 trades of the Gossamer Bio stock since 2019, according to the Form 4 filled with the SEC. Most recently she bought 230,000 units of GOSS stock worth $2,990,000 on 18 September 2020.

The largest trade she's ever made was buying 2,165,800 units of Gossamer Bio stock on 22 February 2019 worth over $5,414,500. On average, Kristina trades about 91,778 units every 16 days since 2017. As of 18 September 2020 she still owns at least 158,734 units of Gossamer Bio stock.

You can see the complete history of Ms. Burow stock trades at the bottom of the page.





Kristina Burow biography

Kristina Burow serves as Independent Director of the Company. She has served as a Managing Director with ARCH Venture Partners, or ARCH, since November 2011 and previously held roles of increasing responsibility at ARCH from August 2002 to November 2011. Ms. Burow also currently serves on the boards of directors of Vividion Therapeutics, Inc., Beam Therapeutics Inc., Sienna Biopharmaceuticals, Inc., Lycera Corp., BlackThorn Therapeutics, Inc., Metacrine, Inc., Scholar Rock, Inc., Unity Biotechnology Inc., AgBiome Inc., Boragen, Inc., AgTech Accelerator and Vir Biotechnology Inc. Ms. Burow previously was a co-founder and director of Receptos prior to its acquisition and of Sapphire Energy, Inc. Prior to ARCH, Ms. Burow was an Associate with the Novartis BioVenture Fund in San Diego and an early employee at the Genomics Institute of the Novartis Research Foundation. Ms. Burow holds a B.A. in Chemistry from the University of California, Berkeley, an M.A. in Chemistry from Columbia University and an M.B.A. from the University of Chicago.

What is the salary of Kristina Burow?

As the Independent Director of Gossamer Bio, the total compensation of Kristina Burow at Gossamer Bio is $329,937. There are 12 executives at Gossamer Bio getting paid more, with Jakob Dupont having the highest compensation of $3,530,450.



How old is Kristina Burow?

Kristina Burow is 46, she's been the Independent Director of Gossamer Bio since 2018. There are 14 older and 2 younger executives at Gossamer Bio. The oldest executive at Gossamer Bio, Inc. is Thomas Daniel, 66, who is the Independent Director.

Insiders trading at Gossamer Bio

Over the last 6 years, insiders at Gossamer Bio have traded over $10,765,709 worth of Gossamer Bio stock and bought 2,039,396 units worth $4,494,757 . The most active insiders traders include Kristina Burow, Faheem Hasnain, and Fund V, L.P.Omega Fund V Gp.... On average, Gossamer Bio executives and independent directors trade stock every 33 days with the average trade being worth of $40,853. The most recent stock trade was executed by Richard Aranda on 24 June 2024, trading 1,908 units of GOSS stock currently worth $1,259.



What does Gossamer Bio do?

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis with and without nasal polyps; and in Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.



What does Gossamer Bio's logo look like?

Gossamer Bio, Inc. logo

Complete history of Ms. Burow stock trades at Unity Biotechnology Inc, Scholar Rock Corp, Vir Biotechnology Inc, Gossamer Bio, Beam Therapeutics, and Metacrine

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
18 Sep 2020 MTCR Metacrine, Inc. Kristina Burow
Director
 Buy 230,000 $13.00 $2,990,000
18 Sep 2020
158,734 ↗
16 Oct 2019 VIR Vir Biotechnology Inc Kristina Burow
Director
 Buy 1,000,000 $20.00 $20,000,000
16 Oct 2019
1,000,000 ↗


Gossamer Bio executives and stock owners

Gossamer Bio executives and other stock owners filed with the SEC include: